MentalHealthDaily

Proton Pump Inhibitors (PPIs) May Treat OCD via Neuronal pH & Dopamine Modulation (2024 Study)

Obsessive-compulsive disorder (OCD), a prevalent neuropsychiatric condition, presents significant treatment challenges due to its varied symptom patterns and poor response to traditional medications. Recent research has revealed a novel approach to treating OCD, focusing on the interplay between dopamine D2 receptor (D2R) agonists and proton pump inhibitors (PPIs). Highlights: OCD’s Complex Treatment Landscape: Traditional treatments …

Reglan (Metoclopramide) For Migraines: An Emergency Abortive Therapy

by GLOOM

Reglan (Metoclopramide) is a medication approved by the FDA for the treatment of gastroparesis or delayed stomach emptying. Gastroparesis often occurs as a result of conditions such as GERD (gastroesophageal reflux disease) and diabetes, but is also sometimes experienced by patients following surgery (post-operative). Assuming an individual postpones treatment of ongoing gastroparesis, stomach acid can …

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

by GLOOM

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …